240(top 25%)
articles
5K(top 21%)
citations
65(top 19%)
★★ articles
0(top 27%)
★★★ articles
2.2(top 27%)
Avg IF
40(top 18%)
H-Index
66(top 19%)
G-Index
130
journals

Most Cited Articles of Ferring Pharmaceuticals in 2008

TitleJournalYearCitations
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerBJU International2008402
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trialHepatology2008157
Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancerEuropean Urology2008103
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North AmericaJournal of Urology200885
Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cyclesReproductive BioMedicine Online200828
Predicting the FSH threshold dose in women with WHO Group II anovulatory infertility failing to ovulate or conceive on clomiphene citrateHuman Reproduction200822
Tobacco and fertility: our responsibilitiesFertility and Sterility200819
Post-Hoc analysis of a head-to-head hyaluronic acid comparison in knee osteoarthritis using the 2004 OMERACT-OARSI responder criteriaClinical Drug Investigation20089
Canadian Association of Gastroenterology Research Committee ReportCanadian Journal of Gastroenterology & Hepatology2008
A review and meta-analysis of hylan versus hyaluronic acid: Comment on the article by Reichenbach et alArthritis and Rheumatism2008